Description:
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian
cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF
pathway.
Title
- Brief Title: Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
- Official Title: Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers
Clinical Trial IDs
- ORG STUDY ID:
HRI-SP-2577-001
- NCT ID:
NCT04611139
Conditions
- SCCOHT
- Ovarian Clear Cell Tumor
- Ovarian Endometrioid Adenocarcinoma
- Endometrial Cancer
Interventions
Drug | Synonyms | Arms |
---|
SP-2577 | | SP-2577 Plus Pembrolizumab |
Pembrolizumab | | SP-2577 Plus Pembrolizumab |
Purpose
Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian
cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF
pathway.
Detailed Description
This study is an open-label, non-randomized dose escalation and expansion study of the LSD
inhibitor SP-2577 in combination with the anti PD- 1 antibody pembrolizumab in patients with
advanced, recurrent small cell ovarian cancer of the hypercalcemic type (SCCOHT) as well as
select additional ovarian and endometrial cancers with mutations in the genes within the
SWI/SNF pathway (Ovarian Clear Cell Cancers (OCCC), Endometrioid Ovarian Cancers (EOC) and
Endometrioid Endometrial Cancers (EEC).
Trial Arms
Name | Type | Description | Interventions |
---|
SP-2577 Plus Pembrolizumab | Experimental | | |
Eligibility Criteria
Inclusion Criteria:
- Female participants who are at least 18 years of age on the day of signing informed
consent with histologically confirmed diagnosis of small cell carcinoma of the ovary
of hypercalcemic type (SCCOHT), ovarian clear cell carcinoma (OCCC), endometrioid
ovarian carcinoma (EOC) or endometrioid endometrial carcinoma (EEC) with confirmed
mutations in one of the SWI/SNF genes (SMARCA4, ARID1A) will be enrolled in this
study.
- Patients must have received at least one prior regimen in the recurrent or advanced
setting and must not be a candidate for other potentially curative treatment options.
- Not pregnant, breastfeeding and agrees to use contraceptive methods if child-bearing
- Provides written informed consent
- Have measurable disease based on RECIST 1.1. Lesions situated in a previously
irradiated area are considered measurable if progression has been demonstrated in such
lesions.
- Have provided archival tumor tissue sample or a newly obtained core or excisional
biopsy of a tumor lesion not irradiated.
- ECOG of 0 to 1
- Adequate organ function
Exclusion Criteria:
- A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation.
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed as long as
patient did not have a serious (≥ Grade 3) immune related AE requiring treatment
discontinuation or treatment with systemic steroids.
- Has received prior therapy with LSD1 targeted agents including monoamine oxidases for
cancer therapy.
- Has received prior systemic anti-cancer therapy including investigational agents
within 4 weeks or 5 half-lives whichever is shorter prior to the first dose of study
treatment.
- Has received prior radiotherapy within 2 weeks of start of study treatment.
- Has received a live vaccine within 30 days prior to the first dose of study drug.
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
- Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years.
- Has known active CNS metastases and/or carcinomatous meningitis.
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs).
- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis.
- Has an active infection requiring systemic therapy.
- Has a known history of HIV, Hepatitis B, or known active Hepatitis C
- Has a known history of active TB
- Has clinically significant, uncontrolled heart disease and/or cardiac repolarization
abnormality
- Is currently receiving any of the following substances and cannot be discontinued 14
days, or 5 half-lives for CYP inhibitors (whichever is shorter) prior to Cycle 1 Day 1
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive within the projected duration
of the study, starting with the screening visit through 120 days after the last dose
of trial treatment.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | Female |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incident of AEs |
Time Frame: | First dose to 90 days after last dose |
Safety Issue: | |
Description: | Incidence of Adverse Events (AEs) as measured by NCI CTCAE version 5.0 |
Secondary Outcome Measures
Measure: | Plasma Concentration of SP-2577 |
Time Frame: | 2 months |
Safety Issue: | |
Description: | Plasma concentration of seclidemstat (SP-2577) |
Measure: | ctDNA in blood and other body fluids |
Time Frame: | 6 months to 2 years |
Safety Issue: | |
Description: | Proportion of circulating tumor DNA ( ctDNA) in peripheral blood and other body fluids e.g. ascitic fluid |
Measure: | Target Inhibition in Tumor Biopsies |
Time Frame: | 6 months to 2 years |
Safety Issue: | |
Description: | Percentage of target inhibition by seclidemstat and pembrolizumab in tumor tissue biopsy specimens |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Not yet recruiting |
Lead Sponsor: | HonorHealth Research Institute |
Last Updated
June 18, 2021